Mepolizumab Beneficial in COPD With Eosinophilic Phenotype
Lower annual rate of moderate, severe exacerbations for patients receiving 100 mg mepolizumab
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Internal Medicine, Allergy, Pharmacy, Pulmonology, Geriatrics, Conference News, Source Type: news
More News: Allergy | Allergy & Immunology | Chronic Obstructive Pulmonary | Conferences | Geriatrics | Internal Medicine | Respiratory Medicine